Immunoglobulin G4-Associated De Novo Autoimmune Hepatitis After Liver Transplantation for Chronic Hepatitis B- and C-Related Cirrhosis and Hepatocellular Carcinoma: A Case Report With Literature Review

2013 ◽  
Vol 45 (2) ◽  
pp. 824-827 ◽  
Author(s):  
X.-y. Zhao ◽  
M.I.A. Rakhda ◽  
T.-I. Wang ◽  
J.-d. Jia
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Transplantation ◽  
Chronic Hepatitis ◽  
Case Report ◽  
Hepatitis B ◽  
Literature Review ◽  
Autoimmune Hepatitis ◽  
Chronic Hepatitis B ◽  
De Novo ◽  
Immunoglobulin G4

No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir

Gut ◽  
2020 ◽  
pp. gutjnl-2019-319867 ◽  
Author(s):  
Feng Su ◽  
Kristin Berry ◽  
George N Ioannou
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Transplantation ◽  
Chronic Hepatitis ◽  
Propensity Score ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Competing Risks ◽  
First Line ◽  
Risk Of Death ◽  
Competing Risks Analysis

ObjectiveEntecavir (ETV) and tenofovir disoproxil fumarate (TDF) are first-line agents for the treatment of chronic hepatitis B (CHB). Recent studies have challenged the assumption that these agents are equally effective at preventing hepatocellular carcinoma (HCC). We aimed to determine whether the risk of HCC and mortality differ in patients with CHB treated with ETV and TDF.DesignWe performed a retrospective cohort study of Veterans Affairs patients with CHB in the USA who initiated treatment with ETV or TDF between the dates of Food and Drug Administration approval of these medications and 1 January 2017. Multivariable Cox proportional hazards regression was used to determine the association between antiviral therapy and HCC risk as well as the risk of death or liver transplantation. Propensity score adjustment and competing risks analysis were performed.ResultsWe identified 2193 ETV-treated and 1094 TDF-treated patients who were followed for a mean of 5.4 years. We found no difference in the risk of HCC in ETV-treated versus TDF-treated patients (adjusted HR (aHR) 1.00, 95% CI 0.76 to 1.32). Results were similar in propensity score adjusted and competing risks analysis, and in multiple sensitivity analyses. We also found no difference in the risk of death or liver transplantation (aHR 1.16, 95% CI 0.98 to 1.39).ConclusionsWe found no difference in the risk of HCC between patients with CHB treated with ETV versus TDF. Our results support current guideline recommendations that both agents are appropriate first-line options for the treatment of CHB.

scholarly journals Hepatic Splenosis Preoperatively Diagnosed as Hepatocellular Carcinoma in a Patient with Chronic Hepatitis B: A Case Report

2008 ◽  
Vol 23 (2) ◽  
pp. 336 ◽  
Author(s):  
Gi-Hong Choi ◽  
Man-Ki Ju ◽  
June-Young Kim ◽  
Chang-Moo Kang ◽  
Kyung-Sik Kim ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Chronic Hepatitis ◽  
Case Report ◽  
Hepatitis B ◽  
Chronic Hepatitis B

Mortality, Liver Transplantation, and Hepatocellular Carcinoma Among Patients With Chronic Hepatitis B Treated With Entecavir vs Lamivudine

2014 ◽  
Vol 147 (1) ◽  
pp. 152-161 ◽  
Author(s):  
Young–Suk Lim ◽  
Seungbong Han ◽  
Nae–Yun Heo ◽  
Ju Hyun Shim ◽  
Han Chu Lee ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Transplantation ◽  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B
Sign in / Sign up

Export Citation Format

Share Document